/
NCNA
$1.58+$0.03 (+1.94%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$6.5M
4M shares
52-week range
$1.33 – $25.58
1% from low
Exchange
NASDAQ
ADRC
Borrow rate
6.20%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-14248.42
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $16.8M | $19.7M | $25.9M | $36.8M | $36.4M | $25.1M | $18.0M | $12.7M |
| Operating income | −$22.0M | −$26.7M | −$32.9M | −$45.3M | −$43.7M | −$32.8M | −$22.8M | −$20.1M |
| EBITDA | $0 | $0 | $0 | −$41.9M | −$52.2M | −$31.8M | −$22.5M | −$20.6M |
| Net income | −$13.8M | −$21.4M | −$30.7M | −$40.5M | −$32.0M | −$27.6M | −$19.0M | −$29.4M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -4.25 | -6.62 | -10.12 | -9.75 | -6.12 | -5.25 | -3.27 | -7.75 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $3M | $-7.99 | $-7.99–$-7.99 | 1 |
| 2027 | $9M | $-51.92 | $-51.92–$-51.92 | 1 |
| 2028 | $19M | $-111.83 | $-111.83–$-111.83 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$9.04
Price
$1.58
Implied upside
+472%
Peer comparison
NuCana plc American Depositary Share
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.
www.nucana.com- Employees
- 12
- IPO / List date
- Sep 28, 2017
Held by traders on TradeandTell
No one on the platform currently holds NCNA.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in NCNA as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-08-11 | 1-for-200reverse |
| 2024-04-16 | 1-for-25reverse |
Recent trades on TradeandTell
No one on the platform has traded NCNA yet.
